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A B S T R A C T
The Rhode Island Department of Corrections (RIDOC) recently implemented the first state-wide, comprehensive
medications for addiction treatment (MAT) program in the US. The objective of this study was to elucidate
perceived barriers for individuals who participated in RIDOC's MAT program while incarcerated. Of the 588
individuals eligible for this study, 227 phone surveys were completed with 214 individuals. Data relevant to
demographic characteristics, probation/parole status, retention in MAT treatment, MAT type received during
incarceration, MAT treatment history, location where they received community treatment, perceived barriers to
treatment, and future goals for MAT were collected. Simple percentages, frequencies, means, and standard
deviations were calculated with SPSS. Most participants (82.4%) reported continuing MAT post-release and a
majority (74.3%) received treatment at an opioid treatment program. Those who did not connect with treatment
post-release reported transportation issues (23.1%) and not wanting to continue MAT (20.5%) as major reasons
for not continuing treatment. The most commonly reported goal for treatment was to continue MAT long-term
(43.5%). Results indicate that most participants linked to MAT treatment post-release. Participants reported
reasons for why they did not continue MAT and had mixed intentions about continuing MAT in the future.
Results provide identification of novel factors, such as side effects, time between release and treatment linkage,
and family and friends' opinions that influence MAT continuation post-incarceration. Results highlight areas of
exploration to influence treatment retention, including the role of probation/parole officers and the potential for
peer support specialists to assist in reducing stigma and increasing interest in MAT.
1. Introduction
Individuals who have recently been incarcerated are at increased
risk of overdose, especially during the first two weeks post-release
(Binswanger et al., 2013). In Rhode Island (RI), among those who had
been recently incarcerated, rates of opioid use disorder (OUD) and
overdose are also amplified. Recently, the risk of overdose has in-
creased due to the prevalence of fentanyl-contaminated heroin in the
drug supply (Brinkley-Rubinstein et al., 2018). In RI in 2015, 70% of
those with criminal justice involvement in the two years before death
had a fentanyl-related overdose, an increase from 38% in 2014.
An effective and evidence-based overdose prevention strategy is
providing access to medication assisted treatment (MAT) to people
during incarceration with linkage to treatment in the community after
release. Because of that, MAT is recommended by the National Institute
of Drug Abuse and the World Health Organization as a first line treat-
ment of OUD (Schuckit, 2016; W.H.O., 2009). Not providing access to
MAT medications denies patients appropriate medical care (National
Academies of Sciences Engineering and Medicine, 2019). The National
Academies of Sciences, Engineering, and Medicine recommends
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2. Methods
Individuals who were released from the RIDOC and were partici-
pants of the MAT program while incarcerated were contacted by phone
between February 2017 and August 2018. Participant release date and
demographic data were collected through RIDOC's electronic record
system. Study inclusion criteria required the participants to be 18 and
older, to meet clinical criteria for OUD, and to have received MAT while
incarcerated at the RIDOC. During the intake process for initiating
treatment, patients signed a form and release authorizing research as-
sistants to contact them about post-release treatment status. During the
discharge planning process, individuals provided a phone number for
contact at post-release. Those who did not have a personal phone
number provided contact information for a significant other and signed
a release to allow research assistants to contact an identified significant
other. Individuals who were incarcerated more than once during the
study period were contacted each time they were released from the
RIDOC. Institutional review board approval was obtained from Brown
University and the Medical Regulations Advisory Group at the RIDOC.
2.1. Data collection
The survey administered to participants included a series of 23
questions that identified post-release treatment status and barriers to
treatment access post-release. The survey was administered by research
assistants with no previous relationships with the subjects. Surveys
were conducted over the phone and all responses were entered into a
Qualtrics database. Participants were asked about their socio-
demographic characteristics such as: probation/parole status, current
living situation, and if they had been arrested since their most recent
release date. In addition, questions about their access to and use of post-
release treatment, barriers to treatment, experience of a non-fatal
overdose since release, and plans for future or continued treatment




A total of 588 individuals were eligible for the study. However, 78
did not provide a personal contact number or sign a release to contact a
significant other, and were, therefore, unreachable post-release.
Subsequently, 510 individuals were called post-release of which 214
were reached (36%). A total of 227 surveys were completed (due to 13
participants being incarcerated multiple times during the study period).
Of the 214 individuals contacted, 78% identified as White, 14%
Hispanic, and 5% as Black. The remaining 3% identified as American
Indian, Asian, other, or unknown. The average age of respondents was
37 years (SD=9) and 77% of respondents were male. A majority of
participants were continued on MAT during incarceration (54%;
n=122) versus initiated soon after commitment (34%, n=77) or in-
ducted before release (12%, n=28). Race, age, gender, MAT status
(e.g., continued MAT from the community), and type of medication
received at RIDOC were compared between participants who were and
were not contacted, with no significant differences between the groups,
except that those who completed the survey were older (M=37,
SD=9 years) than those who did not complete the survey (M=36,
SD=8 years; t(470)= 2.28, p= .03).
Eighty-four percent of respondents were on probation or parole at
the time of survey. A majority were receiving methadone (n=128;
56%) during incarceration at the RIDOC, while 43% (n=97) were on
buprenorphine, and 1% (n=2) received a naltrexone shot upon re-
lease. Surveys were conducted with participants, on average, 28.8
(SD=7.4) days post-release. Most participants were living with family
other than their spouse or partner (44%), 28% with spouse or partner,
20% in temporary housing, and 8% in sober housing or residential
treatment.
3.2. Post-release treatment data
Most participants (n=187, 82%) reported continuing MAT post-
release. Almost all (96%) of those surveyed who entered the facility on
MAT reported continuing with medication post-release. Sixty-five per-
cent of those inducted soon after commitment and 68% of those in-
ducted prior to release reported continued post-release treatment.
Of those who continued MAT, a majority (n=139, 74%) received
treatment at an opioid treatment program, 20% from an office-based
provider, 1% received treatment at a residential program, and 5% re-
ported receiving treatment at another or unclassifiable location. At the
time of survey, 5 (3%) of those who continued with treatment post-
release decided to discontinue and were no longer on MAT.
For those who did not continue on MAT post-release, individuals
reported not connecting with treatment due to transportation issues
(23%), not wanting to continue MAT (21%), perceiving treatment as a
hassle (8%), because of a time lapse between release and connecting
with a community MAT provider (8%), experience of side effects (5%),
cost (5%), and due to family/friends not wanting them to continue MAT
(3%). Four (W.H.O, 2009) individuals reported experiencing a non-fatal
overdose post-release, at on average, 29.3 (SD=41.7) days after
leaving the RIDOC. Of those who overdosed, 2 patients reported they
were not on MAT at the time of overdose. One patient overdosed the
correctional settings provide all FDA approved MAT types and mentions 
that states (National Academies of Sciences Engineering and Medicine, 
2019) MAT provides far reaching benefits including reductions in illicit 
opioid use (Sees et al., 2000), criminal behavior (Deck et al., 2009), 
incarceration (Deck et al., 2009), recidivism (Deck et al., 2009), mor-
tality and overdose risk (Green et al., 2018; Degenhardt et al., 2011), 
HIV risk behaviors (Sharma et al., 2016), and an increase in treatment 
engagement (Sharma et al., 2016; Gordon et al., 2008). However, de-
spite these recommendations and research supporting MAT, in the 
United States, there are few correctional facilities that offer MAT 
(Center, L. A, 2011; Care, N. C. o. C. H, 2018). In 2016, the Rhode 
Island Department of Corrections (RIDOC) introduced the first state-
wide correctional MAT program in the country. The program offers all 
three FDA approved medications (suboxone, methadone, and nal-
trexone) for the treatment of OUD.
The RIDOC MAT program has been associated with a significant 
drop in statewide overdose deaths post-release (Green et al., 2018).The 
program includes screening for OUD as well as continuing and initiating 
individuals on either methadone, buprenorphine, or naltrexone. In-
dividuals who report opiate use or score positive for an OUD on the 
Texas Christian University Drug Screen 5 (Institute of Behavioral 
Research, 2017) are assessed for OUD according to the American So-
ciety of Addiction Medicine Criteria by a clinician. Patients are then 
referred to a medical provider who evaluates and initiates treatment. 
Type of medication prescribed is decided based on a combination of 
clinical considerations, patient past experience and preference, and 
logistical factors (such as MAT options in the patient's community after 
release).
A major component of the RIDOC program is linking patients with 
treatment in the community post-release. A contracted behavioral 
health organization provides much of the treatment inside the facility 
and facilitates continuation of care post-release. Clinicians from the 
contracted behavioral health agency help patients enroll in health in-
surance, set up appointments with and referrals to community provi-
ders. The agency also provides guest dosing for all RIDOC MAT pro-
gram patients, for up to 7 days post-release and at any of the agency's 
locations. In the current study, we followed up with people post-release 
to better understand if they had linked to community treatment and to 
identify any barriers that had prohibited linkage.
day after release (intentional overdose) and had not yet connected with
treatment, then later continued with MAT. One patient had been re-
ceiving MAT when they overdosed post-release (4 days post-release).
Regarding plans for future treatment, 44% of respondents reported
wanting to continue MAT long-term, 37% wanted to eventually dis-
continue MAT, 5% wanted to stop taking MAT as soon as possible, and
2% of respondents had another goal for MAT treatment; 8% were not
receiving MAT at the time of survey but wanted to start receiving MAT
again and 4% were not receiving and had no desire to re-start MAT.
In response to the question “Do you have anything to add about the
MAT program?”, 87 participants provided a response. Results are pre-
sented in Table 1. Comments included both positive (n=40) and ne-
gative (n=43) feedback about the program. The most commonly re-
ported concerns were the length of time from commitment to receiving
treatment (18%), the timing of dosing at RIDOC (12%), stigma from
staff about the MAT program (10%), and perceived program admission
leniency (e.g., believing that people without an OUD frequently are
MAT patients) (5%).
4. Discussion
Results of this study demonstrate that a majority of participants had
linked to community-based MAT post-release. While participants had
varying plans for their continuation of treatment (longer or short-term),
most participants connected with and were satisfied with the treatment
they received in the community. The low rates of individuals (National
Academies of Sciences Engineering and Medicine, 2019) who initially
connected with post-release treatment and then discontinued support
this conclusion. In addition, participants that had not connected to
treatment gave key reasons why: transportation, a time lapse between
release and access to MAT, side effects, and preferences of friends and
family.
Response rates for this study were notable at 36% of eligible par-
ticipants, in comparison to data that shows many phone-based survey
studies without incentives can have much lower response (about 9%)
when compared to those with incentives (24–32%) (Keeter et al., 2017;
Link et al., 2007) Additionally, demographic data and MAT status at
RIDOC (e.g., initiated soon after commitment), generally matched be-
tween those were reached vs not reached. These groups were relatively
similar with respect to the data we collected on both.
Our findings echo those of other studies that have made clear the
connection between access to MAT while incarcerated and continued
uptake of MAT in the community after release (Sharma et al., 2016;
Gordon et al., 2008). For instance, a review conducted by Sharma et al.
(2016) found that in four randomized control trials, those who received
MAT during incarceration were more likely to continue treatment in the
community post-release (Sharma et al., 2016). Importantly, for those
who stop MAT after release, this study elucidates potential targets for
maintaining MAT use long-term.
A novel finding of this study is the identification of factors post-
release that may affect linkage to and initiation of MAT post-release.
Transportation is a known barrier to care during community re-entry
(Sung et al., 2011; La Vigne, 2008; Begun et al., 2016). However,
perhaps more relevant to MAT, were participants responses related to
time between release and linkage, side effects, and family and friends'
opinions about MAT. These have clear implications for intervention to
improve uptake of MAT in the community such as making sure that
linkage to community-based treatment post-release is timely, including
education about possible side effects of each type of MAT, and pro-
viding information about alternative types of MAT if side effects are
experienced. Where cost is of concern, community supports can be
utilized to access payments methods (e.g. signing people up for Medi-
caid before release).
Finally, it is well documented that there is stigma related to MAT.
Previous research has found that some people may have hesitations
about using MAT because they conceptualize it as at odds with ab-
stinence only approaches to recovery (Olsen and Sharfstein, 2014).
Corrections-based overdose education and naloxone provision pro-
grams have recently had some success in providing information to fa-
mily and friends who visit people who are incarcerated (Huxley-Reicher
et al., 2018). These campaigns could be expanded to include informa-
tion relevant to MAT and the importance of MAT to combat overdose
risk during community re-entry.
Probation/parole officers (PPOs) may play an important role in
maintaining MAT during release in that over 84% of this sample was on
probation/parole. Importantly, partnerships with community providers
well versed in engagement and linkage could be of assistance in
maintaining MAT for persons on probation/parole. In particular, Peer
Recover Support Specialists (PRSS) have lived experience and have
been found to be effective at assisting in long-term recovery, motiva-
tion, access to resources (e.g., transportation, social support), and ser-
vices engagement (Kunicki et al., 2018; Gagne et al., 2018). At the very
least, for the almost 10% of the sample not on MAT but who wanted to
restart MAT after release, this is a missed opportunity for engagement.
What's more, there are likely probationers/parolees released from in-
carceration who are not started on MAT due to rapid release (e.g. very
short stays at the RIDOC). PPOs are ideally positioned to partner with
community agencies, and in particular PRSS to complete screening,
assessment, and use of MAT.
4.1. Limitations
A major limitation of this study is that the results do not take into
account the 64% of eligible participants not reached. Therefore, overall
treatment retention rates for the majority of the sample are unclear.
Also, although the study included participants with racial, ethnic and
Concerns N=43
Time to receive treatment (N=16)
• Took a week before got methadone, was getting ready to leave before put on
methadone, going through withdrawals, took almost a month to get treatment
• Would like if the program could get to people faster, didn't get suboxone for four or
five days when committed”
• 18 days to get methadone, experienced withdrawal• didn't see a doctor once, uncomfortable the whole time he was there, went in on a
dose but was never seen, put in 20 slips for a higher dose
Stigma from staff (N=9)
• COs [correctional officers] at the ACI [RIDOC] called him a junkie when he went
for medication at night.
• Liked the CODAC [behavioral healthcare organization providing services] part of
the program, but said the COs made offensive remarks, might not know the full
effects of the program. As for medical staff (nurses) he said they need to be more
knowledgeable about MAT, said that some of the staff acted like the COs in terms of
MAT.
Dose timing (N=10)a
• Inmates should get suboxone in the morning, not at night, because it keeps him
awake, or to split dose-1 in AM and 1 in PM
• Upset that we give it at 9 pm, says that is causes inmates to “bounce off the walls”.
Would prefer that the medication dosing is more spaced out.
Program admission leniency (N=4)
• Upset that we give it to everyone “giving it away like it's candy”.• don't prioritize patients who really need medication, people who are in for long
periods of time and then get prescribed MAT are doing it just to get high
Positive feedback N=40
• Happy that they started doing it in the RIDOC, a lot of people came in sick and
ended up as a butterfly in the chapel.
• It was great, helped when needed it, able to stay in OTP [opioid treatment program]
after release
• It's helping a lot of people! Really big help for him. Used the same day when he was
released before the program started, but thought the program was amazing!
Percentages and counts may not add to 100% due to some comments containing
both concerns and positive feedback.
a Based on feedback the medication dispensing time was moved to the
morning.
Table 1
Responses to the question “Do you have anything to add about the MAT pro-
gram?”, 87 participants.
5. Conclusion
MAT begun during incarceration is effective in that a majority of
persons maintain use an average of one month after release. Many have
family support available, although in some cases, social supports dis-
couraged continued MAT use. PRSS may be an important solution in
addressing barriers to continued use, including engagement in services.
Preparing participants for potential side effects, and additional MAT
options may be important in maintaining MAT in the community.
Further investigations should focus on how PPOs, familial relationships,
and support networks facilitate or hinder MAT post-release.
Partnerships with treatment agencies offering comprehensive MAT in-
cluding PRSS and behavioral interventions may be of use.
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gender diversity that generally matched the demographics of eligible 
participants not contacted, a majority of participants were White, non-
Hispanic, adult males, which may limit the generalizability of results.
The survey also included individuals who chose to participate with 
no incentive, so self-selection bias may limit the representativeness of 
this sample with respect to all MAT program participants. Additionally, 
because this survey was based solely on participant self-report, answers, 
it is unclear if self-report bias influenced participant honesty and va-
lidity of the results.
Whether some forms of MAT were stopped more frequently than 
others was not examined, nor was switching between types of MAT. It 
may be that participants need access to more options in order to 
maintain MAT, including longer-acting injectable naltrexone—espe-
cially since transportation was an issue. In order to keep interviews 
relatively brief, this study did not evaluate facilitators of MAT in the 
community . Although some social support detracted from MAT use, 
many participants lived with family who may be supportive of MAT. 
Participants were followed an average of a month after release. 
Extending follow-up would be important to determine numbers who 
stopped MAT at further follow-up and why.
Finally , it is important to study barriers and facilitators for PPOs 
with respect to probationer/parolee MAT use. Certainly, in some sys-
tems multiple legal entities (e.g., courts, public defender, district at-
torney) are needed to remove barriers and facilitate PPOs engagement 
with clients related to MAT.
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